Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
The return on equity (ROE) is -66.49%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation.
Limited quarterly history available
ROE needs at least three reported quarters before a meaningful chart is shown.
RETURN ON EQUITY (ROE)
-66.49%
RETURN ON EQUITY (ROE) AVG TTM
N/A
RETURN ON EQUITY (ROE) AVG 3Y
N/A
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
-58.27%
vs the sector median at left
YD Bio Limited Ordinary Shares
Market Cap
$435.61M
Return on Equity (ROE)
-66.49%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$438.07M
Return on Equity (ROE)
-97.92%
TTM Avg
-59.21%
3Y Avg
-49.84%
5Y Avg
-46.25%
Market Cap
$431.97M
Return on Equity (ROE)
-160.85%
TTM Avg
-225.75%
3Y Avg
-186.61%
5Y Avg
-129.85%
Market Cap
$439.55M
Return on Equity (ROE)
-0.01%
TTM Avg
-61.70%
3Y Avg
-96.25%
5Y Avg
-81.28%
Market Cap
$442.34M
Return on Equity (ROE)
-16.43%
TTM Avg
-26.04%
3Y Avg
-38.16%
5Y Avg
-45.00%
Market Cap
$426.51M
Return on Equity (ROE)
-1721.80%
TTM Avg
-73.40%
3Y Avg
-45.77%
5Y Avg
-18.46%
Market Cap
$445.71M
Return on Equity (ROE)
-52.56%
TTM Avg
-31.09%
3Y Avg
-101.75%
5Y Avg
-86.54%
Market Cap
$424.10M
Return on Equity (ROE)
-6.60%
TTM Avg
-10.82%
3Y Avg
-11.36%
5Y Avg
-7.59%
Market Cap
$422.86M
Return on Equity (ROE)
-38.32%
TTM Avg
-35.34%
3Y Avg
12.60%
5Y Avg
10.50%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| YD Bio Limited Ordinary Shares (YDES) | $435.61M | -66.49% | N/A | N/A | N/A |
| DiaMedica Therapeutics Inc. (DMAC)vs › | $438.07M | -97.92% | -59.21% | -49.84% | -46.25% |
| NeuroPace, Inc. (NPCE)vs › | $431.97M | -160.85% | -225.75% | -186.61% | -129.85% |
| Assembly Biosciences, Inc. (ASMB)vs › | $439.55M | -0.01% | -61.70% | -96.25% | -81.28% |
| Ovid Therapeutics Inc. (OVID)vs › | $442.34M | -16.43% | -26.04% | -38.16% | -45.00% |
| ARS Pharmaceuticals, Inc. (SPRY)vs › | $426.51M | -1721.80% | -73.40% | -45.77% | -18.46% |
| Capricor Therapeutics, Inc. (CAPR)vs › | $445.71M | -52.56% | -31.09% | -101.75% | -86.54% |
| NeoGenomics, Inc. (NEO)vs › | $424.10M | -6.60% | -10.82% | -11.36% | -7.59% |
| Tectonic Therapeutic, Inc. (TECX)vs › | $422.86M | -38.32% | -35.34% | 12.60% | 10.50% |
| Tilray Brands, Inc. (TLRY)vs › | $422.72M | -9.23% | -76.14% | -50.80% | -36.67% |
ROE
-66.5%
ROA
-29.6%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2024-12-31 | -34.97% |
